Comparative Pharmacology
Head-to-head clinical analysis: EVEKEO versus PEMOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVEKEO versus PEMOLINE.
EVEKEO vs PEMOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.
Pemoline is a central nervous system stimulant that enhances dopaminergic and noradrenergic transmission by blocking the reuptake of dopamine and norepinephrine at the synaptic cleft. It also has mild monoamine oxidase inhibitory activity.
5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.
Oral, 37.5 mg once daily in the morning; may increase by 18.75 mg weekly to a maximum of 112.5 mg/day (divided into 2 doses if total dose > 75 mg).
None Documented
None Documented
Terminal elimination half-life: 2-3 hours. Clinical context: Short half-life supports multiple daily dosing for seizure control. May be prolonged in hepatic impairment.
Terminal elimination half-life is 8-12 hours in children; 12-16 hours in adults. Steady-state is reached within 2-3 days.
Renal: 30-50% as unchanged drug; fecal: 50-70% as metabolites and unchanged drug.
Pemoline is primarily excreted renally as unchanged drug (40-50%) and metabolites; approximately 20-30% is excreted in feces via biliary elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant